D

Deepcell

Microfluidics-based cell analysis and sorting

Overview

Deepcell provides high-content single-cell analysis and sorting through its REM-I platform, which combines label-free imaging, microfluidics, and AI to profile cells by their shape and internal features. The system images cells in microfluidic channels, uses deep learning to interpret morphology and other high-dimensional signals, and can gently sort cells based on these readouts while collecting rich data. It differentiates itself by seamlessly integrating microfluidics with AI-driven, label-free phenotyping to deliver detailed, single-cell readouts without chemical labels. Its goal is to give researchers and pharma teams precise cellular phenotyping and sorting to speed up discovery and drug development with data-rich insights at the single-cell level.

Work here?Claim your company

About Deepcell

Simplify's Rating
Why Deepcell is rated
C
Rated B on Competitive Edge
Rated C on Growth Potential
Rated D+ on Differentiation

Industries

Data & AnalyticsAI & Machine LearningBiotechnologyHealthcare

Company Size

11-50

Company Stage

Late Stage VC

Total Funding

$178M

Headquarters

Sunnyvale, California

Founded

2015

Get referred to Deepcell

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 20, 2026 Gilead validates REM-I for biotherapeutic cell-line development.
  • 2025 Mayo Clinic IVF collaboration expands potential clinical and reproductive workflows.
  • First commercial REM-I installation and 2026 AACR presence show real market adoption.

What critics are saying

  • Headcount fell from 115 in 2023 to 38 by March 2026.
  • Deepcell had zero active job postings in 2026, signaling constrained growth.
  • A 2024 layoff post shows prior workforce cuts; another financing failure threatens survival.

What makes Deepcell unique

  • REM-I pairs label-free imaging with AI sorting for viable single-cell morphology reads.
  • August 2026 Gilead collaboration builds a CHO foundation model on REM-I.
  • September 2026 REM-I OnSite offers fully on-premises deployment for regulated labs.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$178M

Above

Industry Average

Funded Over

4 Rounds

Notable Investors:
Late VC funding comparison data is currently unavailable. We're working to provide this information soon!
Late VC Funding Comparison Coming Soon

Growth & Insights and Company News

Headcount

6 month growth

-5%

1 year growth

3%

2 year growth

-8%
Intelligence360 News
Oct 26th, 2022
Menlo Park California Based Deepcell Is Raising $80,000,095.00 In New Equity Investment.

Menlo Park, CA – According to filings with the U.S. Securities and Exchange Commission, Deepcell is raising $80,000,095.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Mahdokht Masaeli played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development. About Deepcell

Clinical Omics
Dec 9th, 2020
Deepcell receives financing of $20M in Series A financing

Deepcell, a developer of artificial intelligence-based cell classification and isolation technologies spun out of Stanford University in 2017, said this week it has completed a $20 million Series A financing.

Finsmes
Dec 7th, 2020
Deepcell Closes $20M Series A Funding Round

Deepcell, a Mountain View, Calif.-based life science company pioneering AI-powered cell classification and isolation for cell biology and translational research, closed its Series A round of financing with $20m. The round was led by Bow Capital and joined by Andreessen Horowitz, which led its $5m seed round. Other investors include 50Y, DCVC, Stanford University, and […]

Recently Posted Jobs

Sign up to get curated job recommendations

There are no jobs for Deepcell right now.

Find jobs on Simplify and start your career today

We update Deepcell's jobs every few hours, so check again soon! Browse all jobs